...
search icon
dnli-img

Denali Therapeutics Inc, Common Stock

DNLI

NSQ

$12.7

+$0.2

(1.6%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.87B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.63M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.58
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$10.57 L
$33.33 H
$12.7

About Denali Therapeutics Inc, Common Stock

Denali Therapeutics Inc., discovers, develops, and delivers barrier-crossing therapeutics for neurodegenerative, lysosomal, and other serious diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; DNL921 Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameDNLISectorS&P500
1-Week Return7.81%-0.29%3.55%
1-Month Return-15.56%-7.65%-5.72%
3-Month Return-35.17%-4.64%-9.82%
6-Month Return-54.64%-12.35%-9.51%
1-Year Return-33.75%-4.34%1.26%
3-Year Return-57.69%-3.64%19.2%
5-Year Return-33.61%43.5%90.39%
10-Year Return-40.79%83.13%151.51%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue335.66M48.66M108.46M330.53M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":14.5,"profit":true},{"date":"2022-12-31","value":32.31,"profit":true},{"date":"2023-12-31","value":98.47,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue212.62M5.61M7.03M16.73M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.64,"profit":true},{"date":"2022-12-31","value":3.31,"profit":true},{"date":"2023-12-31","value":7.87,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit335.66M48.66M101.43M313.81M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":14.5,"profit":true},{"date":"2022-12-31","value":30.22,"profit":true},{"date":"2023-12-31","value":93.49,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%100.00%93.52%94.94%-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.52,"profit":true},{"date":"2023-12-31","value":94.94,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses272.94M344.41M449.21M527.23M501.88M[{"date":"2020-12-31","value":51.77,"profit":true},{"date":"2021-12-31","value":65.32,"profit":true},{"date":"2022-12-31","value":85.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":95.19,"profit":true}]
Operating Income62.72M(295.75M)(340.74M)(196.70M)(487.34M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-471.56,"profit":false},{"date":"2022-12-31","value":-543.3,"profit":false},{"date":"2023-12-31","value":-313.62,"profit":false},{"date":"2024-12-31","value":-777.04,"profit":false}]
Total Non-Operating Income/Expense18.48M9.19M29.55M96.54M129.27M[{"date":"2020-12-31","value":14.3,"profit":true},{"date":"2021-12-31","value":7.11,"profit":true},{"date":"2022-12-31","value":22.86,"profit":true},{"date":"2023-12-31","value":74.68,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income71.96M(291.16M)(325.97M)(145.19M)(422.70M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-404.61,"profit":false},{"date":"2022-12-31","value":-452.99,"profit":false},{"date":"2023-12-31","value":-201.77,"profit":false},{"date":"2024-12-31","value":-587.42,"profit":false}]
Income Taxes823.00K(575.00K)21.00K30.00K(68.00K)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-69.87,"profit":false},{"date":"2022-12-31","value":2.55,"profit":true},{"date":"2023-12-31","value":3.65,"profit":true},{"date":"2024-12-31","value":-8.26,"profit":false}]
Income After Taxes71.14M(290.58M)(325.99M)(145.22M)(422.64M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-408.49,"profit":false},{"date":"2022-12-31","value":-458.26,"profit":false},{"date":"2023-12-31","value":-204.15,"profit":false},{"date":"2024-12-31","value":-594.13,"profit":false}]
Income From Continuous Operations72.78M(290.58M)(325.99M)(124.43M)(422.77M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-399.25,"profit":false},{"date":"2022-12-31","value":-447.9,"profit":false},{"date":"2023-12-31","value":-170.96,"profit":false},{"date":"2024-12-31","value":-580.88,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income71.14M(290.58M)(325.99M)(145.22M)(422.77M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-408.49,"profit":false},{"date":"2022-12-31","value":-458.26,"profit":false},{"date":"2023-12-31","value":-204.15,"profit":false},{"date":"2024-12-31","value":-594.32,"profit":false}]
EPS (Diluted)0.26(2.39)(2.60)(1.08)(2.67)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-919.23,"profit":false},{"date":"2022-12-31","value":-1000,"profit":false},{"date":"2023-12-31","value":-415.38,"profit":false},{"date":"2024-12-31","value":-1026.92,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

DNLI
Cash Ratio 8.14
Current Ratio 8.46

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

DNLI
ROA (LTM) -24.82%
ROE (LTM) -37.40%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

DNLI
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

DNLI
Trailing PE NM
Forward PE NM
P/S (TTM) 3643.65
P/B 1.48
Price/FCF NM
EV/R 2843.16
EV/Ebitda NM

FAQs

What is Denali Therapeutics Inc share price today?

Denali Therapeutics Inc (DNLI) share price today is $12.7

Can Indians buy Denali Therapeutics Inc shares?

Yes, Indians can buy shares of Denali Therapeutics Inc (DNLI) on Vested. To buy Denali Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DNLI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Denali Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Denali Therapeutics Inc (DNLI) via the Vested app. You can start investing in Denali Therapeutics Inc (DNLI) with a minimum investment of $1.

How to invest in Denali Therapeutics Inc shares from India?

You can invest in shares of Denali Therapeutics Inc (DNLI) via Vested in three simple steps:

  • Click on Sign Up or Invest in DNLI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Denali Therapeutics Inc shares
What is Denali Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Denali Therapeutics Inc (DNLI) is $33.33. The 52-week low price of Denali Therapeutics Inc (DNLI) is $10.57.

What is Denali Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Denali Therapeutics Inc (DNLI) is 1.48

What is the Market Cap of Denali Therapeutics Inc?

The market capitalization of Denali Therapeutics Inc (DNLI) is $1.87B

What is Denali Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Denali Therapeutics Inc is DNLI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top